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Abstract
Background: Natural product structures have high chemical diversity and are attractive as lead structures for discovery of
new drugs. One of the disease areas where natural products are most frequently used as therapeutics is oncology.
Method and Findings: A library of natural products (NCI Natural Product set) was screened for compounds that induce
apoptosis of HCT116 colon carcinoma cells using an assay that measures an endogenous caspase-cleavage product. One of
the apoptosis-inducing compounds identified in the screen was thaspine (taspine), an alkaloid from the South American
tree Croton lechleri. The cortex of this tree is used for medicinal purposes by tribes in the Amazonas basin. Thaspine was
found to induce conformational activation of the pro-apoptotic proteins Bak and Bax, mitochondrial cytochrome c release
and mitochondrial membrane permeabilization in HCT116 cells. Analysis of the gene expression signature of thaspine-
treated cells suggested that thaspine is a topoisomerase inhibitor. Inhibition of both topoisomerase I and II was observed
using in vitro assays, and thaspine was found to have a reduced cytotoxic effect on a cell line with a mutated topoisomerase
II enzyme. Interestingly, in contrast to the topoisomerase II inhibitors doxorubicin, etoposide and mitoxantrone, thaspine
was cytotoxic to cell lines overexpressing the PgP or MRP drug efflux transporters. We finally show that thaspine induces
wide-spread apoptosis in colon carcinoma multicellular spheroids and that apoptosis is induced in two xenograft mouse
models in vivo.
Conclusions: The alkaloid thaspine from the cortex of Croton lechleri is a dual topoisomerase inhibitor effective in cells
overexpressing drug efflux transporters and induces wide-spread apoptosis in multicellular spheroids.
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Introduction
The concept of developing target-specific drugs for treatment of
cancer has not been as successful as initially envisioned [1,2]. The
success rate of oncology drugs from first-in-man to registration
during 1991–2000 was only around 5% for 10 major pharma
companies [2]. A major causes of attrition in the clinic is lack of
drug efficacy [2]. This realization has lead to a renewed interest in
the use of bioassays for drug development in the field of oncology.
One attractive screening endpoint is apoptosis since this form of
cell death is induced by many clinically used (and effective)
anticancer agents [3].
Natural products have been used as source of novel therapeutics
for many years. Natural products have been selected during evolution
to interact with biological targets and their high degree of chemical
diversity make them attractive as lead structures for discovery of new
drugs [4]. A number of plant-derived anticancer drugs have received
FDA approval for marketing: taxol, vinblastine, vincristine, topote-
can, irinotecan, etoposide and teniposide [5]. Antibiotics from
Streptomyces species, including bleomycins, dactinomycin, mitomy-
cin, and the anthracyclines daunomycin and doxorubicin are
important anticancer agents [6]. More recently developed anticancer
agents such as the Hsp90 inhibitor geldanamycin was also isolated
from Streptomyces [7]. Marine organisms have also been used as
source for the search of anticancer agents. Interesting compounds,
including bryostatin (from the marine bryozan Bugula neritina),
ecteinascidin (an alkaloid from the Carribian tunicate, Ecteinascidia
turbinata) and dolastatin (from the sea hare), have been identified [8].
Although being the source of lead compounds for the majority
of anticancer drugs approved by the Food and Drug Administra-
tion, natural products have largely been excluded from modern
screening programs. We here used a high-throughput method for
apoptosis detection [9] to screen a library of natural compounds
using a human colon carcinoma cell line as screening target. One
of the most interesting hits in this screen was thaspine, an alkaloid
from the cortex of the South American tree Croton lechleri. We show
that thaspine is a topoisomerase inhibitor which is active on cells
overexpressing drug efflux transporters.
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Screening for natural products that induce apoptosis of
colon carcinoma cells
We used HCT116 colon carcinoma cells as target cells to screen
for apoptosis-inducing agents present in NCI Natural Product Set
(www.dtp.nci.nih.gov). Apoptosis was determined using a modifi-
cation of the M30-ApoptosenseH method [9] which specifically
measures caspase-cleaved cytokeratin 18 formed in apoptotic cells.
Activity in this assay is inhibited by the pan-caspase inhibitor
zVAD-fmk [9]. The M30-ApoptosenseH method is a useful
screening tool since it measures the accumulation of the apoptotic
product in cell cultures, leading to an integrative determination of
apoptosis to the point of harvesting the cells. Using a compound
concentration of 25 mM and an exposure time of 24 hours, 20
compounds were identified as inducing apoptosis above a
preselected threshold value (Table 1). Molecular targets have
been reported on 14 of these 20 compounds (Table 1). The
alkaloid thaspine (taspine; NSC76022) was one of the remaining 6
compounds with unknown mechanism of action (Figure 1A).
Thaspine is of interest since it is an alkaloid from Dragon’s blood,
a latex prepared from the cortex of the tree Croton lechleri and used
by tribes in the Amazonas basin for medicinal purposes. Thaspine
induced strong caspase-cleavage of cytokeratin-18 in HCT116
cells at a concentration of ,10 mM (Fig. 1B). This concentration
requirement is similar to that of other cancer therapeutic drugs
such as cisplatin (,20 mM), doxorubicin (,3 mM) and mechlor-
ethamine (,20 mM) for induction of caspase activity of this cell
line (Fig. 1B). Thaspine was also found to induce activation of
caspase-3 at 10 and 16 hours (see below).
Thaspine induces apoptosis in vivo
Thaspine has previously been described to have anti-tumor
activity in the mouse S180 sarcoma model [10]. To examine
whether in vivo anti-tumor activity is associated with induction of
apoptosis, SCID mice carrying HCT116 xenografts were treated
with thaspine and tumor sections were stained with an antibody to
active caspase-3. Positivity was observed in tumor tissue at
48 hours after treatment with 10 mg/kg thaspine (maximally
tolerated dose) (Fig. 2A, top). We also utilized caspase-cleaved
CK18 as a plasma biomarker for tumor apoptosis [11,12]. When
applied to human xenografts transplanted to mice, this method
allows determination of tumor apoptosis independently of host
toxicity (the antibodies used in the ELISA assay are species-specific
and do not detect mouse caspase-cleaved CK18 [13]). We
examined two different xenograft models using this assay, the
HCT116 colon carcinoma used for screening and the FaDu head-
neck carcinoma model. In order to mimic a clinical trial situation
of advanced disease, tumors were allowed to grow to a size of
,400 mm
3 and then treated with a single injection of thaspine.
Increases in CK18-Asp396 were observed 48 hours after injection
of thaspine in both models (Figure 2B, C). Apoptosis was
paralleled by a significant, but transient, reduction of tumor size
in the FaDu model (Figure 2D). We conclude that thaspine is
capable of inducing tumor apoptosis in vivo.
Figure 1. Induction of apoptosis by thaspine. (A) chemical structure of thaspine (NSC76022); (B) induction of caspase-cleaved CK18 by thaspine,
cisplatin, doxorubicin and mechlorethamine in HCT116 colon carcinoma cells. Treatment was for 24 hours with the indicated concentrations of
compounds. Cells were lysed and CK18-Asp396 was determined using the M30 CytoDeath ELISA. Results are shown with S.D. from triplicate
determinations. Similar results (including the biphasic response to doxorubicin) were observed in independent experiments.
doi:10.1371/journal.pone.0007238.g001
Table 1. Compounds in the NCI Natural Product Set that
induce caspase cleavage of CK18 in HCT116 cells.
NSC number Name Target Reference
5159 Chartreusin DNA [45]
19941 Champaca camphor
26258 Rotenone Electron transport [46]
42076 Podophyllotoxin derivative Microtubuli [47]
62709 Streptonigrin Topoisomerase II [48]
76022 Thaspine [10]
82151 Daunorubicin Topoisomerase II [49]
114344 Ascochitine Protein phophatase [50]
114568 Eupachlorin acetate
122023 Valinomycin K+ ionophore [51]
135758 Piperazinedione DNA alkylator [52]
153858 Maytansine Microtubuli [53]
226080 Rapamycin mTOR [54]
234161 Deoxyliatrigramin
250430
285116 Siomycin A FoxM1 [55]
287088 Physalin B Proteasome [56]
287456 Pacifenol
332598 Rhizoxin Microtubuli [57]
333856 Tetrocarcin A Bcl-2 [58]
doi:10.1371/journal.pone.0007238.t001
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Most forms of cancer therapeutics induce the mitochondrial
pathway of apoptosis [3]. This pathway is associated with opening
of the mitochondrial permeability transition pore [14]. We
examined whether thaspine induced a decrease in HCT116
mitochondrial membrane potential (DyM) using the fluorescent
probe tetramethyl-rhodamine ethyl ester (TMRE). Mitochondria
in thaspine-treated cells underwent a shift to lower DyM values
(Figure 3A). A hallmark of the mitochondrial apoptosis pathway is
release of cytochrome c from mitochondria to the cytosol.
Thaspine was found to induce a decrease in the levels of
mitochondrial cytochrome c and an increase of the levels in the
cytosol (Figure 3B). The Bcl-2 family proteins Bak and Bax are key
regulators of the mitochondrial apoptosis pathway [15]. During
apoptosis, the conformation of these proteins is altered. Experi-
ments using conformation-specific antibodies showed that thaspine
induce conformational activation of both Bak and Bax (Figure 3C).
BH3-only proteins antagonize the pro-survival function of Bcl-2
proteins [16] or may activate pro-apoptotic Bak/Bax [17]. We
used an siRNA approach to examine whether any particular BH3-
only proteins were required for thapsin-induced apoptosis.
Transfection with 9 different siRNA pools showed that Bid and
Bik siRNA significantly reduced thaspin-induced cytokeratin 18
caspase-cleavage in HCT116 cells (Fig. 3D), suggesting that these
proteins are regulators of apoptosis elicited by this compound.
Thaspine is a topoisomerase inhibito
The molecular target of thaspine is not known. To generate
hypotheses regarding the mechanism of action, we used the
Connectivity Map (CMAP) [18], which is a large compendium of
gene expression signatures from drug-treated cell lines. We
analyzed the drug-induced gene expression changes compared to
vehicle control in the breast cancer cell line MCF-7, since all of the
1,309 compounds in CMAP have been tested on this cell line. The
gene expression response to thaspine was similar to that of
ellipticine, a known topoisomerase II inhibitor, and similar to the
response to the topoisomerase I inhibitor camptothecin
(Figure 4A).
Topoisomerase inhibition was tested using in vitro enzyme
assays. The results showed that thaspine inhibits both topoisom-
erase I and II activity at the apoptotic concentration (10 mM)
(Figure 4B, C). Furthermore, thaspine was found to have a
reduced cytotoxic effect on the viability on CEM/VM-1, a cell line
selected for resistance to the topoisomerase II inhibitor teniposide
compared to the parental cell line CCRF-CEM (Table 2). CEM/
VM-1 harbors a mutated topoisomerase II gene which mediates a
specific resistance to topoisomerase II inhibitors, but not general
multidrug resistance [19,20]. CCRF-CEM are not resistant to
camptothecin [21]. The resistance to thaspine was not as
pronounced as seen for etoposide, known to be a non-intercalating
topoisomerase II inhibitor, but well in line with the intercalating
topoisomerase inhibitors doxorubicin and mitoxantrone. These
data further suggest that thaspine is a topoisomerase inhibitor.
Thaspine induced an accumulation of HCT116 cells in the S
and G2/M phases of the cell cycle (Table 3). For comparison, the
topoisomerase II inhibitor etoposide induced G2/M accumula-
tion, whereas camptothecin induced some S-phase arrest (Table 3).
Thaspine cytotoxicity is only weakly affected by PgP or
MRP overexpression
Anticancer drugs are often substrates of membrane-associated
drug efflux transporters. The topoisomerase II inhibitor doxoru-
bicin is a substrate of P-glycoprotein (Pgp, ABCB1) and etoposide
is a substrate of the multidrug resistance-associated protein (MRP,
Figure 2. In vivo induction of tumor apoptosis by thaspine. (A) Induction of apoptosis in HCT116 tumors in vivo. SCID mice were injected with
10 mg/kg thaspine. Mice were sacrificed after 48 hours and tumors stained for active caspase-3 (upper panel: thaspine treated mice; lower panel: PBS
injected mice). (B, C) SCID mice carrying HCT116 tumors (B) or FaDu head-neck carcinoma tumors (C) were injected with 10 mg/kg of thaspine or with
PBS and the levels of human caspase-cleaved CK18 (CK18-Asp396) were determined in mouse plasma 48 hours after treatment using ELISA. The
antibodies used to detect CK18-Asp396 do not bind mouse CK18. Four mice in each group; bars represent S.D. (D) SCID mice carrying FaDu tumors
were treated with 10 mg/kg of thaspine (day 1, arrow) and tumor volume was calculated; black circles: untreated mice, red squares: treated mice (4
mice in each group). Error bars are presented as unidirectional for figure clarity. Animals were sacrificed when tumors were approximately 1 cm
3
according to local animal welfare regulations. Statistical significance was calculated using Student’s t-test.
doi:10.1371/journal.pone.0007238.g002
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to etoposide and/or doxorubicin due to PgP or MRP over-
expressio [22] were ,2-fold resistant to thaspine compared to
parental cells (Table 2).
Thaspine induces apoptosis in multicellular spheroids
Multicellular spheroids (MCS) are known to better mimic
human solid tumor tissue than 2-D monolayer cultures. Many
clinically used anticancer drugs show limited potency on MCS, a
phenomenon believed to reflect their limited activity on solid
tumors [23,24]. To investigate whether thaspine induces apoptosis
of MCS, spheroids were formed from HCT116 and used after 5
days of incubation. At this point in time, cell proliferation in the
MCS was largely confined to peripheral cell layers (Fig. 5, top left,
staining for Ki67) and some spontaneous apoptosis was observed
in deeper cell layers (Fig. 5, top right, staining for active caspase-3).
Following drug treatment, MCS were fixed, sectioned and stained
for active caspase-3. Activation of caspase-3 was observed in MCS
after 10 hours of treatment with thaspine, and wide-spread
activation after 16 hours of treatment (Fig. 5). Cells in the central
portions of MCS did not stain positive for active caspase-3 even at
the time of spheroid disintegration. To determine cell survival,
spheroids were trypsinized and cells were plated at low density to
determine clonogenicity. Clonogenic survival of cells from
spheroids treated with 10 mM thaspine was 0.006% of cells from
control spheroids. These data show that thaspine treatment was
Figure 3. Induction of the mitochondrial apoptosis pathway by thaspine. (A) loss of mitochondrial membrane potential in thaspine-treated
HCT116 cells. Control and thaspine-treated cells (10 mM, 18 hours) were stained with tetramethyl-rhodamine ethyl ester (TMRE) and fluorescence was
measured by flow cytometry; (B) Release of cytochrome c to the cytosol of thaspine-treated cells. Cells were treated with 10 mM thaspine for 7 or
16 hours. Cytochrome c was quantified in mitochondrial and cytosolic fractions by Western blotting. (C) thaspine induces the active conformation of
Bak and Bax. Cells were treated with 10 mM thaspine, fixed and stained with conformation-specific antibodies to Bak and Bax. Note induction of the
active conformation of both molecules by thaspine (red arrows: immunofluorescent signal in untreated cells; green arrows: immunofluorescent signal
in drug-treated cells). (D) Inhibition of thaspine-induced apoptosis by siRNA to Bik and Bid. Cells were transfected with siRNAs in triplicate 96 well
plates and treated with thaspine or solvent (see Material and Methods). After 24 hours the levels of caspase-cleaved CK18 were determined using the
M30 CytoDeath ELISA.
doi:10.1371/journal.pone.0007238.g003
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not by apoptosis. Cisplatin and doxorubicin did not induce wide-
spread apoptosis in HCT116 MCS (Fig. 5).
Discussion
We here screened a collection of natural products for their
capacity to induce apoptosis of colon carcinoma cells. Natural
products are known to have a high chemical diversity [4], a
necessity for drug discovery in the oncology field [25]. This
approach lead to the identification of 20 agents that induced
strong increases in the levels of caspase-cleaved cytokeratin 18 in
colon carcinoma cells. Several of these compounds are well known
to have anti-tumor activity (e.g. podophyllotoxin, daunorubicin,
maytansine, rapamycin and rhizoxin). Of the remaining com-
pounds we noted thaspine (taspine), an alkaloid present in the
cortex of the South American tree Croton lechleri. Thaspine is of
interest since Croton lechleri is used in traditional medicine. A red
latex, Dragon’s blood, is extracted from the tree cortex and used
by tribes of the Amazonian basin for several purposes, including
wound healing, as an anti-inflammatory agent, and to treat cancer
[26,27]. Thaspine was previously reported to be cytotoxic
[26,28,29], anti-angiogenic [30], and to have antitumor activity
[28]. Consistent with these previous reports, we found that
thaspine treatment induced caspase activation in tumor tissue and
release of human caspase-cleaved CK18 from tumor cells into the
blood of SCID mice.
Our connectivity map analysis showed that thaspine induced a
similar gene expression pattern as the topoisomerase inhibitors
ellipticine and camptothecin. Direct measurements of enzyme
activity confirmed that both topoisomerase I and II were inhibited
by relevant concentrations of thaspine. Furthermore, CEM/VM-1
cells, which express a mutated form of topoisomerase II resistant to
inhibitors of this enzyme [19,20], showed increased resistance to
thaspine. Topoisomerases are enzymes which have important roles
in DNA metabolism by adjusting the number of supercoils in the
DNA molecule - a key requirement for transcription and
Figure 4. Thaspine is a topoisomerase inhibitor. (A) Connectivity Map (CMAP) results after treatment with thaspine. The bar view is constructed
from 6100 horizontal lines, each representing a single treatment and ordered according to their corresponding enrichment to the query signatures
generated after thaspine treatment. Black horizontal lines in the barview represent the individual instances for ellipticine and camptothecin when the
thaspine expression signature was used as query signature. Score according to the CMAP database; (B) inhibition of topoisomerase I activity: 1:
plasmid +5U topoisomerase I; 2: plasmid; 3: plasmid +5U topoisomerase I+DMSO (1 mm); 4. Marker for nicked plasmid; 5: plasmid +5U topoisomerase
I +50 mM thaspine; 6: plasmid +5U topoisomerase I +25 mM thaspine; 7: plasmid +5U topoisomerase I +10 mM thaspine; 8: plasmid + DMSO (1 mm).
Topoisomerase I primarily induced nicked plasmid DNA, note the inhibition by thaspine. (C) inhibition of topoisomerase II activity: 1: plasmid +15U
topoisomerase II; 2: plasmid; 3: plasmid +15U topoisomerase II + DMSO (1 mm); 4. Marker for nicked plasmid; 5: plasmid +15U topoisomerase II
+50 mM thaspine; 6: plasmid +15U topoisomerase II +25 mM thaspine; 7: plasmid +15U topoisomerase II +10 mM thaspine; 8: plasmid + DMSO (1 mm).
Topoisomerase II primarily induced nicked plasmid DNA, note the inhibition by thaspine.
doi:10.1371/journal.pone.0007238.g004
Table 2. Influence of resistance mechanisms on cytotoxic
potency of thaspine and standard topoisomerase inhibitors.
Topo II
associated
P-gp
associated
MRP
associated
Parental cell line CCRF-CEM RPMI 8226 NCI-H69
Resistant cell line CEM/VM-1 8226/Dox40 H69AR
Thaspine 4.8 1.8 1.1
Doxorubicin 3.9 87.0 13.5
Etoposide 12.0 13.0 61.6
Mitoxantrone 4.6 10.4 1.7
The resistance factor was defined as the IC50 value in the resistant subline
divided by that in its parental cell line. The IC50 of thaspine on the parental cell
lines were between 1–3 mM. Topo II, Topoisomerase II; P-gp, P-glycoprotein
(ABCB1); MRP, multidrug resistance-associated protein (ABCC1). For details on
cell lines and calculations of resistance factors, see [22]. CCRF-CEM are not
resistant to camptothecin [21], which was therefore not included. The
experiments were repeated twice.
doi:10.1371/journal.pone.0007238.t002
Table 3. Effects of thaspine and reference compounds on the
HCT116 cell cycle.
G1 (percent) S (percent) G2 (percent)
Control 37.8+6.1 37.0+0.4 25.1+5.8
Thaspine 13.5+2.7 49.6+2.2 36.9+2.5
Etoposide 11.1+2..9 42.1+1.2 46.7+3.4
Camptothecin 35.3+1.1 50.4+1.7 14.3+1.9
doi:10.1371/journal.pone.0007238.t003
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strand breaks in DNA, while topoisomerase II can break both
strands. A variety of clinically used anticancer drugs inhibit the
action of topoisomerase I [31,32] or topoisomerase II [33]. The
topoisomerase I inhibitors topotecan and irinotecan are among the
most effective drugs used to treat colorectal, small cell lung and
ovarian cancer [31]. Topotecan and irinotecan are chemically
unstable and large efforts are being made to develop improved
compounds [32]. A large number of compounds have been
described to inhibit topoisomerase II, including the important
clinical agents doxorubicin/adriamycin and etoposide [33]. A
limited number of agents can inhibit both enzymes and may have
strong antitumor activity [34]. Some agents such as intoplicine, the
acridine XR5000 (DACA) bind to DNA by intercalation [35],
others are physically linked inhibitors of topoisomerase I and
topoisomerase II.
Drug resistance is the most important cause of cancer treatment
failure and represents a major challenge to the treatment and
eradication of cancer. Drug resistance is known to be multifac-
torial. One important mechanism of resistance to clinically used
DNA damaging anticancer drugs is the expression of ABC
transporters such as Pgp and MRP [36]. Thaspine cytotoxicity was
only marginally affected by overexpression of the P-glycoprotein
(Pgp, ABCB1) or the multidrug resistance-associated protein
(MRP, ABCC1). Another mechanism of resistance of solid tumors
to anticancer drugs is multicellular-mediated resistance [37]. This
form of resistance has been found to influence the effect of
adriamycin on solid tumors, partly due to limited drug penetration
into the tumor parenchyme [38,39]. Interestingly, thaspine was
found to induce wide-spread apoptosis of multicellular spheroids.
This property is interesting considering that many clinically used
anticancer drugs show limited potency on spheroids, possibly
reflecting their limited activity on solid tumors [23,24]. The
therapeutical potential of thaspine on solid tumors is therefore
interesting to examine. Such studies require optimization of drug
formulation (thaspine is hydrophobic; XlogP =2.8) and evaluation
of how thaspine should be combined with other drugs.
Only a fraction of the diversity of the biosphere has been tested
for biological activity. The approach to screen chemically diverse
drug libraries for apoptosis-inducing compounds and to use the
Connectivity Map resource [18] for unveiling the mechanisms of
action of the compounds identified is reasonably straight-forward.
We believe that this approach may be effective in anticancer drug
discovery.
Materials and Methods
Compounds
The NCI Natural Product Set was obtained from the
Developmental Therapeutics Program of the US National Cancer
Institute (http://www.dtp.nci.nih.gov).
Cell culture and screening
HCT116 colon carcinoma cells (from the American Type
Culture Collection, ATCC) were maintained in McCoy’s 5A
modified medium/10% fetal calf serum at 37uCi n5 %C O 2.
Multicellular spheroids were formed from HCT116 cells as
described [40]. For description and of cell lines MCF-7, CCRF-
CEM, CEM/VM1, RPMI 8226, NCI-H69, H69AR see [22].
Cells were seeded in 96 well plates at 10,000 cells per well.
Compounds were added to a concentration of 25 mM in a final
concentration of 1% DMSO; control wells received 1% DMSO
only. After 24 hours of drug treatment, NP40 was added to the
culture medium to 0.1% to extract caspase-cleaved CK18 from
cells and to include material released to the medium from dead
cells. Caspase-cleaved cytokeratin-18 (CK18-Asp396) was deter-
mined using 25 ml medium/extract using the M30 CytoDeath
ELISA assay (a variant of the M30-ApoptosenseH ELISA [9]
developed for in vitro use (Peviva AB, Bromma, Sweden)). Signals
were factorised to percent of a staurosporine reference (quadruple
wells used on each plate at 1 mM) and compounds that induced a
signal .60% of staurosporine were selected for study.
Resistance mediated by efflux proteins and mutated topoisom-
erase II was evaluated using the fluorometric microculture
cytotoxicity assay (FMCA) [41]. The resistance factor was defined
as the IC50 value in the resistant subline divided by that in its
parental cell line [42].
siRNA transfection. HCT116 cells were transfected in 96
well plates with siRNAs to BH-3 only proteins using HiPerfect
transfection reagents as recommended by the manufacturer (all
Figure 5. Thaspine induces wide-spread activation of caspase-
3 in spheroids. HCT116 spheroids with homogeneous diameters were
formed using the hanging drop technique as described [40]. Five days
after formation spheroids were compact and contained proliferating
cells only in the surface layers (Ki67 staining, top left). Spheroids were
treated with drugs for the times indicated, fixed, sectioned and stained
for active caspase-3. Thaspine was used at 20 mM, doxorubicin at
20 mM, and cisplatin at 40 mM.
doi:10.1371/journal.pone.0007238.g005
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siRNAs were used (final concentration 25 nM) for triplicate wells
for each siRNA pool. After 54 hours of incubation, thaspine or
solvent was added to the wells of the 96 well plates and incubation
was continued for 18 hours. CK18-Asp396 was then determined
using the M30 CytoDeath ELISA as described above.
Immunological assays
Conformational changes resulting in exposure of inaccessible N-
terminal epitopes of Bak and Bax were determined using flow
cytometry [43]. Conformation-specific antibody to Bak was
obtained from Oncogene Research Products) (AM03, clone
TC100) and to Bax from BD Bioscieces PharMingen (clone
6A7; San Diego, CA). The increases in accessibility of the epitopes
was monitored using the FL1 channel of a FACScalibur flow
cytometer (BD, Franklin Lakes, NJ) as previously described [44].
Tumor or spheroid sections were deparaffinized with xylene,
rehydrated and microwaved and then incubated over-night with
the primary antibodies diluted in 1% (wt/vol) bovine serum
albumin and visualized by standard avidin–biotin–peroxidase
complex technique (Vector Laboratories, Burlingame, CA, USA).
Counterstaining was performed with Mayer’s haematoxylin.
Antibody against active caspase-3 was from Pharmingen (used
1:50) and antibody to Ki67 (MIB-1) was from Immunotech SA,
Marseille, France (used at 1:150).
Mitochondrial Membrane Permeability Transition
Loss of mitochondrial membrane potential was monitored using
tetramethyl-rhodamine ethyl ester (TMRE) from Molecular
Probes (Eugene, OR). Fluorescence was measured by flow
cytometry.
Assay of cytochrome c release
HCT116 cells were treated with 10 mM thaspine and harvested
at 7 or 16 hours. After washing with PBS, cells were resuspended
in 500 mL (10 mM NaCl, 1.5 mM CaCl2, 10 mM Tris, pH 7.5)
and incubated for 20 min on an ice bath. After passing 10 times
through a 40 gauge needle, 400 mL mitochondrial buffer (210 mM
mannitol, 70 mM sucrose, 20 mM Hepes-KOH, pH 7.5, and
1 mM EDTA containing 0.45% bovine serum albumin (BSA)) was
added and nuclei were pelleted by centrifugation for 1000 xg for
10 min at +4uC. The supernatant was trasferred to a new tube and
centrifuged for 30 min at maximal speed in an Eppendorf
centrifuge at +4uC. Supernatant and pellet fractions were analysed
by Western blotting (cytochrome c antibody ab33484 from Abcam
used at 1:1000).
Connectivity Map
The Connectivity Map (CMAP) (www.broad.mit.edu/cmap)
build 02 contains genome-wide expression data for 1300
compounds (6100 instances, including replicates, different doses
and cell lines). We followed the original protocol using MCF-7
breast cancer cells as described by Lamb et al [18]. Briefly, cells
were seeded in a 6-well plate at a density of 0.4610
6 cells per well.
Cells were left to attach for 24 h, followed by exposure to thaspine
at a final concentration of 10 mM, or to vehicle control (DMSO).
After 6 h treatment, the cells were washed with PBS and total
RNA was prepared using RNeasy miniprep kit (Qiagen, Chats-
worth, CA). Starting from two micrograms of total RNA, gene
expression analysis was performed using Genome U133 Plus 2.0
Arrays according to the GeneChip Expression Analysis Technical
Manual (Rev. 5, Affymetrix Inc., Santa Clara, CA). Raw data was
normalized with MAS5 (Affymetrix) and gene expression ratios for
drug treated vs. vehicle control cells were calculated to generate
lists of regulated genes. Filter criteria were present call for all genes
in the treated cell line and an expression cut-off of at least 100
arbitrary expression units. Only probes present on HG U133A
were used, for CMAP compatibility. The 40 most up and down
regulated genes (i.e. probes) were uploaded and compared to the
6100 instances in the CMAP database, to retrieve a ranked
compound list. Raw and normalized expression data have been
deposited at Gene Expression Omnibus (http://www.ncbi.nlm.
nih.gov/geo/) with accession number GSE13124.
Topoisomerase enzyme assays
Tests of topoisomerase inhibition were performed using kits
from TopoGen Inc. (Port Orange, FLA) according to the
instructions of the manufacturer. All incubations were performed
in the presence of solvent (DMSO) for 30 minutes at 37uC
followed by agarose gel electrophoresis in the absence of ethidium
bromide. Gels were stained with ethidium bromide, washed and
photographed.
Treatment of mouse xenografts and determination of
caspase-cleaved CK18 in mouse plasma
HCT116 or FaDu tumors were grown as subcutaneous
xenografts in SCID mice (4 mice in each group; each injected
with 10
6 cells). When tumors had grown to a size of approximately
400 mm
3 (somewhat larger than the generally used size; a larger
tumor size leads to better sensitivity using the biomarker assay),
mice were injected with thaspine subcutaneously and tumor size
measured daily. The dose used (10 mg/kg) was tolerated by the
mice (toxicity was observed at 20 mg/kg). FaDu cells express high
levels of CK18 which is released to the extracellular compartment
and into the blood from dying cells. Mice were sacrificed 48 hours
after injection of thaspine and EDTA-plasma was collected.
Caspase-cleaved CK18 (CK18-Asp396) was measured in 12.5 mL
of plasma using the M30-ApoptosenseH assay (Peviva AB,
Bromma). Each sample was mixed with 0.4 mL of heterophilic
blocking reagent (HBR-Plus purified, part#3KC579; Scantibodies
laboratory Inc, Santee CA, USA). Animal experiments were
conducted in full accordance with Swedish governmental statutory
regulations on animal welfare under permission from ethical
committees (permit N295/06 Stockholms norra djurfo ¨rso ¨ksetiska
na ¨mnd).
Acknowledgments
We are grateful to Juan Castro for help with flow cytometry, to Hanna
Go ¨ransson and Maria Ryda ˚ker at the Uppsala Array Platform.
Author Contributions
Conceived and designed the experiments: WF MF STL. Performed the
experiments: WF MF SB MHO. Analyzed the data: WF MF SB MHO RL
STL. Wrote the paper: WF MF RL STL.
References
1. Nygren P, Larsson R (2003) Overview of the clinical efficacy of investigational
anticancer drugs. J Intern Med 253: 46–75.
2. Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates?
Nat Rev Drug Discov 3: 711–715.
3. Kaufmann SH, Earnshaw WC (2000) Induction of apoptosis by cancer
chemotherapy. Exp Cell Res 256: 42–49.
4. Koehn FE, Carter GT (2005) The evolving role of natural products in drug
discovery. Nat Rev Drug Discov 4: 206–220.
Novel Topoisomerase Inhibitor
PLoS ONE | www.plosone.org 7 October 2009 | Volume 4 | Issue 10 | e72385. Srivastava V, Negi AS, Kumar JK, Gupta MM, Khanuja SP (2005) Plant-based
anticancer molecules: a chemical and biological profile of some important leads.
Bioorg Med Chem 13: 5892–5908.
6. Arcamone FM (1998) From the pigments of the actinomycetes to third
generation antitumor anthracyclines. Biochimie 80: 201–206.
7. Uehara Y (2003) Natural product origins of Hsp90 inhibitors. Curr Cancer Drug
Targets 3: 325–330.
8. da Rocha AB, Lopes RM, Schwartsmann G (2001) Natural products in
anticancer therapy. Curr Opin Pharmacol 1: 364–369.
9. Ha ¨gg M, Biven K, Ueno T, Rydlander L, Bjo ¨rklund P, et al. (2002) A novel
high-through-put assay for screening of pro-apoptotic drugs. Invest New Drugs
20: 253–259.
10. Zhang YM, He LC, Wang HY (2007) [Inhibitory effect of taspine on mouse
S180 sarcoma and its mechanism]. Zhongguo Zhong Yao Za Zhi 32: 953–956.
11. Kramer G, Erdal H, Mertens HJ, Nap M, Mauermann J, et al. (2004)
Differentiation between cell death modes using measurements of different
soluble forms of extracellular cytokeratin 18. Cancer Res 64: 1751–1756.
12. Cummings J, Ward TH, Greystoke A, Ranson M, Dive C (2008) Biomarker
method validation in anticancer drug development. Br J Pharmacol 153:
646–656.
13. Olofsson MH, Cummings J, Fayad W, Brnjic SRH, et al. Specific demonstration
of drug-induced tumour cell apoptosis in human xenografts models using a
plasma biomarker. Cancer Biomarkers in press.
14. Lemasters JJ, Nieminen AL, Qian T, Trost LC, Elmore SP, et al. (1998) The
mitochondrial permeability transition in cell death: a common mechanism in
necrosis, apoptosis and autophagy. Biochim Biophys Acta 1366: 177–196.
15. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, et al. (2001)
Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction
and death. Science 292: 727–730.
16. Labi V, Erlacher M, Kiessling S, Villunger A (2006) BH3-only proteins in cell
death initiation, malignant disease and anticancer therapy. Cell Death Differ 13:
1325–1338.
17. Gavathiotis E, Suzuki M, Davis ML, Pitter K, Bird GH, et al. (2008) BAX
activation is initiated at a novel interaction site. Nature 455: 1076–1081.
18. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, et al. (2006) The
Connectivity Map: using gene-expression signatures to connect small molecules,
genes, and disease. Science 313: 1929–1935.
19. Danks MK, Schmidt CA, Cirtain MC, Suttle DP, Beck WT (1988) Altered
catalytic activity of and DNA cleavage by DNA topoisomerase II from human
leukemic cells selected for resistance to VM-26. Biochemistry 27: 8861–8869.
20. Bugg BY, Danks MK, Beck WT, Suttle DP (1991) Expression of a mutant DNA
topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to
teniposide. Proc Natl Acad Sci U S A 88: 7654–7658.
21. Jonsson E, Fridborg H, Csoka K, Dhar S, Sundstrom C, et al. (1997) Cytotoxic
activity of topotecan in human tumour cell lines and primary cultures of human
tumour cells from patients. Br J Cancer 76: 211–219.
22. Wickstro ¨m M, Danielsson K, Rickardson L, Gullbo J, Nygren P, et al. (2007)
Pharmacological profiling of disulfiram using human tumor cell lines and human
tumor cells from patients. Biochem Pharmacol 73: 25–33.
23. Sutherland RM, Durand RE (1976) Radiation response of multicell spheroids–
an in vitro tumour model. Curr Top Radiat Res Q 11: 87–139.
24. Sutherland RM (1988) Cell and environment interactions in tumor micro-
regions: the multicell spheroid model. Science 240: 177–184.
25. Lloyd DG, Golfis G, Knox AJ, Fayne D, Meegan MJ, et al. (2006) Oncology
exploration: charting cancer medicinal chemistry space. Drug Discov Today 11:
149–159.
26. Pieters L, de Bruyne T, Claeys M, Vlietinck A, Calomme M, et al. (1993)
Isolation of a dihydrobenzofura lignan from South American Dragon’s Blood
(Croton Spp.) as an inhibitor of cell proliferation. J of Natural Products 56:
899–906.
27. Perdue GP, Blomster RN, Blake DA, Farnsworth NR (1979) South American
plants II: taspine isolation and anti-inflammatory activity. J Pharm Sci 68:
124–126.
28. Zhang YM, He LC (2007) [Study on thaspine in inducing apoptosis of A549
cell]. Zhong Yao Cai 30: 429–432.
29. Itokawa H, Ichihara Y, Mochizuki M, Enomori T, Morita H, et al. (1991) A
cytotoxic substance from Sangre de Grado. Chem Pharm Bull (Tokyo) 39:
1041–1042.
30. Zhang Y, He L, Meng L, Luo W, Xu X (2008) Suppression of tumor-induced
angiogenesis by taspine isolated from Radix et Rhizoma Leonticis and its
mechanism of action in vitro. Cancer Lett.
31. Pommier Y (2006) Topoisomerase I inhibitors: camptothecins and beyond. Nat
Rev Cancer 6: 789–802.
32. Teicher BA (2008) Next generation topoisomerase I inhibitors: Rationale and
biomarker strategies. Biochem Pharmacol 75: 1262–1271.
33. Nitiss JL (2009) Targeting DNA topoisomerase II in cancer chemotherapy. Nat
Rev Cancer 9: 338–350.
34. Denny WA, Baguley BC (2003) Dual topoisomerase I/II inhibitors in cancer
therapy. Curr Top Med Chem 3: 339–353.
35. Dittrich C, Dieras V, Kerbrat P, Punt C, Sorio R, et al. (2003) Phase II study of
XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-
h infusion in patients with advanced ovarian cancer. Invest New Drugs 21:
347–352.
36. Ling V (1997) Multidrug resistance: molecular mechanisms and clinical
relevance. Cancer Chemother Pharmacol 40 Suppl: S3–8.
37. Kobayashi H, Man S, Graham CH, Kapitain SJ, Teicher BA, et al. (1993)
Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc
Natl Acad Sci U S A 90: 3294–3298.
38. Durand RE (1981) Flow cytometry studies of intracellular adriamycin in
multicell spheroids in vitro. Cancer Res 41: 3495–3498.
39. Erlichman C, Vidgen D (1984) Cytotoxicity of adriamycin in MGH-U1 cells
grown as monolayer cultures, spheroids, and xenografts in immune-deprived
mice. Cancer Res 44: 5369–5375.
40. Herrmann R, Fayad W, Schwarz S, Berndtsson M, Linder S (2008) Screening
for compounds that induce apoptosis of cancer cells grown as multicellular
spheroids. J Biomol Screen 13: 1–8.
41. Lindhagen E, Nygren P, Larsson R (2008) The fluorometric microculture
cytotoxicity assay. Nat Protoc 3: 1364–1369.
42. Wickstrom M, Danielsson K, Rickardson L, Gullbo J, Nygren P, et al. (2007)
Pharmacological profiling of disulfiram using human tumor cell lines and human
tumor cells from patients. Biochem Pharmacol 73: 25–33.
43. Griffiths GJ, Dubrez L, Morgan CP, Jones NA, Whitehouse J, et al. (1999) Cell
damage-induced conformational changes of the pro-apoptotic protein Bak in
vivo precede the onset of apoptosis. J Cell Biol 144: 903–914.
44. Mandic A, Viktorsson K, Molin M, Akusjarvi G, Eguchi H, et al. (2001)
Cisplatin induces the proapoptotic conformation of bak in a deltamekk1-
dependent manner. Mol Cell Biol 21: 3684–3691.
45. Yagi M, Nishimura T, Suzuki H, Tanaka N (1981) Chartreusin, an antitumor
glycoside antibiotic, induces DNA strand scission. Biochem Biophys Res
Commun 98: 642–647.
46. Chance B, Williams GR, Hollunger G (1963) Inhibition of electron and energy
transfer in mitochondria. I. Effects of Amytal, thiopental, rotenone, progester-
one, and methylene glycol. J Biol Chem 238: 418–431.
47. Gupta RS (1983) Podophyllotoxin-resistant mutants of Chinese hamster ovary
cells: cross-resistance studies with various microtubule inhibitors and podophyl-
lotoxin analogues. Cancer Res 43: 505–512.
48. Yamashita Y, Kawada S, Fujii N, Nakano H (1990) Induction of mammalian
DNA topoisomerase II dependent DNA cleavage by antitumor antibiotic
streptonigrin. Cancer Res 50: 5841–5844.
49. Bodley A, Liu LF, Israel M, Seshadri R, Koseki Y, et al. (1989) DNA
topoisomerase II-mediated interaction of doxorubicin and daunorubicin
congeners with DNA. Cancer Res 49: 5969–5978.
50. Seibert SF, Eguereva E, Krick A, Kehraus S, Voloshina E, et al. (2006)
Polyketides from the marine-derived fungus Ascochyta salicorniae and their
potential to inhibit protein phosphatases. Org Biomol Chem 4: 2233–2240.
51. Levinson C (1967) Effect of valinomycin on net sodium and potassium transport
in Ehrlich ascites tumour cells. Nature 216: 74–75.
52. Brockman RW, Shaddix SC, Williams M, Struck RF (1976) Studies with 2,5-
piperazinedione, 3,6-bis(5-chloro-2-piperidyl)-,dihydrochloride. II. Effects on
macromolecular synthesis in cell culture and evidence for alkylating activity.
Cancer Treat Rep 60: 1317–1324.
53. York J, Wolpert-DeFilippes MK, Johns DG, Sethi VS (1981) Binding of
maytansinoids to tubulin. Biochem Pharmacol 30: 3239–3243.
54. Baldo P, Cecco S, Giacomin E, Lazzarini R, Ros B, et al. (2008) mTOR
pathway and mTOR inhibitors as agents for cancer therapy. Curr Cancer Drug
Targets 8: 647–665.
55. Radhakrishnan SK, Bhat UG, Hughes DE, Wang IC, Costa RH, et al. (2006)
Identification of a chemical inhibitor of the oncogenic transcription factor
forkhead box M1. Cancer Res 66: 9731–9735.
56. Vandenberghe I, Creancier L, Vispe S, Annereau JP, Barret JM, et al. (2008)
Physalin B, a novel inhibitor of the ubiquitin-proteasome pathway, triggers
NOXA-associated apoptosis. Biochem Pharmacol 76: 453–462.
57. Takahashi M, Iwasaki S, Kobayashi H, Okuda S, Murai T, et al. (1987)
Rhizoxin binding to tubulin at the maytansine-binding site. Biochim Biophys
Acta 926: 215–223.
58. Nakashima T, Miura M, Hara M (2000) Tetrocarcin A inhibits mitochondrial
functions of Bcl-2 and suppresses its anti-apoptotic activity. Cancer Res 60:
1229–1235.
Novel Topoisomerase Inhibitor
PLoS ONE | www.plosone.org 8 October 2009 | Volume 4 | Issue 10 | e7238